AU2018210165A1 - PparƳ agonist for the treatment of huntington's disease - Google Patents

PparƳ agonist for the treatment of huntington's disease Download PDF

Info

Publication number
AU2018210165A1
AU2018210165A1 AU2018210165A AU2018210165A AU2018210165A1 AU 2018210165 A1 AU2018210165 A1 AU 2018210165A1 AU 2018210165 A AU2018210165 A AU 2018210165A AU 2018210165 A AU2018210165 A AU 2018210165A AU 2018210165 A1 AU2018210165 A1 AU 2018210165A1
Authority
AU
Australia
Prior art keywords
subject
disease
huntington
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018210165A
Other languages
English (en)
Inventor
Barbara FINCK
Lawrence Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherus Oncology Inc
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of AU2018210165A1 publication Critical patent/AU2018210165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018210165A 2017-01-18 2018-01-18 PparƳ agonist for the treatment of huntington's disease Abandoned AU2018210165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447741P 2017-01-18 2017-01-18
US62/447,741 2017-01-18
PCT/US2018/014240 WO2018136635A1 (en) 2017-01-18 2018-01-18 Pparϒ agonist for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
AU2018210165A1 true AU2018210165A1 (en) 2019-08-01

Family

ID=62908392

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018210165A Abandoned AU2018210165A1 (en) 2017-01-18 2018-01-18 PparƳ agonist for the treatment of huntington's disease

Country Status (13)

Country Link
US (1) US20190350918A1 (https=)
EP (1) EP3570841A4 (https=)
JP (1) JP2020505448A (https=)
KR (1) KR20190122664A (https=)
CN (1) CN110461330A (https=)
AU (1) AU2018210165A1 (https=)
BR (1) BR112019014529A2 (https=)
CA (1) CA3050104A1 (https=)
EA (1) EA201991716A1 (https=)
IL (1) IL268008A (https=)
MX (1) MX2019008535A (https=)
SG (1) SG11201906644YA (https=)
WO (1) WO2018136635A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895541B2 (en) * 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP2008515978A (ja) * 2004-10-13 2008-05-15 ユニバーシティ オブ コネチカット カンナビネルジック脂質リガンド
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
EP2448412B1 (en) * 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途

Also Published As

Publication number Publication date
IL268008A (en) 2019-09-26
CA3050104A1 (en) 2018-07-26
BR112019014529A2 (pt) 2020-02-27
EA201991716A1 (ru) 2020-02-04
EP3570841A4 (en) 2020-08-19
KR20190122664A (ko) 2019-10-30
MX2019008535A (es) 2019-12-02
EP3570841A1 (en) 2019-11-27
WO2018136635A1 (en) 2018-07-26
JP2020505448A (ja) 2020-02-20
CN110461330A (zh) 2019-11-15
US20190350918A1 (en) 2019-11-21
SG11201906644YA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
NZ745778A (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
JP2008519847A (ja) 運動障害の治療方法
US20100063116A1 (en) Use of pramipexole or a salt thereof for the treatment of parkinson's disease
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
EP2343976A1 (en) Methods of using sustained release aminopyridine compositions
Zafonte et al. Antispasticity medications: uses and limitations of enteral therapy
CN114728012A (zh) 用于治疗癫痫持续状态的加奈索酮
JP2021519349A (ja) 幻覚とそれに関連する病態の治療のための方法および組成物
US20090149518A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
CN110996951A (zh) 治疗进行性核上性麻痹的PPARγ激动剂
US20190350918A1 (en) PPARy AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE
RU2763425C2 (ru) Терапевтические агенты для нейродегенеративных заболеваний
CN102143686A (zh) 用4-氨基吡啶持续治疗脱髓鞘病患者
JP2002541198A (ja) 失禁の治療法
Ciccone Geriatric pharmacology
US20240342160A1 (en) Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
JP6420923B1 (ja) 医薬
TW202539621A (zh) 用於治療巴金森氏症的治療劑
AU2024244089A1 (en) Methods of dosing spinogenic compounds
RU2849887C2 (ru) Терапевтические средства против нейродегенеративных заболеваний
Roller et al. Parkinsonism and parkinson's disease
CN108025003A (zh) 前额叶皮质处理病症，步态和肢体障碍治疗
US20230404955A1 (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere’s disease, tourette’s syndrome, attention deficit hyperactivity disorder and addiction
JP2006509773A (ja) 持続性アレルギー性鼻炎の治療のためのレボセチリジンの使用

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application